Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Complera, Eviplera, emtricitabine/tenofovir/rilpivirine
Also known as: Truvada TMC278 combination
print preview
bookmark
share with colleague
General Information
Company
Gilead Sciences Inc.
Description
Fixed-dose combination of the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir and the non-nucleoside reverse transcriptase inhibitor rilpivirine
Molecular Target
HIV reverse transcriptase
Mechanism of Action
HIV reverse transcriptase inhibitor
Latest Stage of Development
Marketed
Indication
HIV / AIDS
Partner
Johnson & Johnson
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy